BAAM
RLAY icon

Baker Avenue Asset Management’s Relay Therapeutics RLAY Stock Holding History

Baker Avenue Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$214 – 1700
2023
Q2 		$214 Buy
+17
New +$211 ﹤0.01% 1570

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Baker Avenue Asset Management's RLAY Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Relay Therapeutics (RLAY) in Q3 2023, closing a stake of 17 shares — an estimated $214 sold.

Baker Avenue Asset Management first reported a position in RLAY in Q2 2023 and held it in 1 quarter. The position peaked at $214 in Q2 2023. 172 funds tracked by Wall St. Rank hold RLAY as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Relay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 17 Relay Therapeutics shares in Q3 2023, an estimated $214.
  • Baker Avenue Asset Management first reported a position in Relay Therapeutics in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Relay Therapeutics position peaked at $214 in Q2 2023.
  • 172 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.